Next Generation Kinase Inhibitors Summit

Celebrating 20 years of FDA approval and high efficacy profiles, kinase inhibitors have changed the face of oncology treatment. However, increasing resistance and safety issues limit the success of existing kinase inhibitor classes.

The inaugural Next Generation Kinase Inhibitors Summit is the only industry-focused meeting dedicated to applying novel kinase biology to drug development and innovating existing programs to produce the next wave of kinase inhibitor drugs which are able to show efficacious and durable clinical response in oncology and beyond.

Boasting 20+ speakers, 1 deep-dive workshop and over 3 days of unrivalled content spanning discovery, R and D and clinical development, this event is a unique opportunity for your team to identify and target the undruggable, elevate drug design for improved target selectivity, overcome the blood brain barrier and rationalize combinations for more durable responses.

Collaborate with 80+ senior drug developers in March to achieve the next generation of these kinase inhibitor therapies with optimized specificity, maximal durability to deliver the best clinical outcomes.

URLs:
Brochure: https://go.evvnt.com/944626-0?pid=176 
Tickets: https://go.evvnt.com/944626-1?pid=176 
Website: https://go.evvnt.com/944626-2?pid=176 

Date and Time: On Tue, Mar 29, 22 ( 1:00 PM) - Thu, Mar 31, 22 ( 4:45 PM)

Prices:
Industry Pricing - Conference Only: USD 2999.00,
Industry Pricing - Conference + 1 Workshop : USD 3648.00,
Academic pricing - Conference Only : USD 2599.00,
Academic pricing - Conference + 1 Workshop: USD 3148.00,
Service Provider Pricing - Conference Only : USD 3599.00,
Service Provider Pricing - Conference + 1 Workshop: USD 4348.00

Speakers: Leslie Cousens, Senior Director, Search and Evaluation, Respiratory and Immunology, AstraZeneca, Markus Queisser, Scientific Director, GlaxoSmithKline, Tony Hunter, Professor, Salk Institute, Jan S. Rosenbaum, Ph.D, CEO and CSO, Kurome Therapeutics, Lewis Cantley, Professor of Cancer Biology, Cornell University, Steve Fruchtman, President and CEO, Onconova Therapeutics, Harish Dave, CMO, AUM Biosciences, Matt Lucas, SVP, Drug Discovery, Black Diamond, Milton Werner, Founder, President and CEO, Inhibikase Therapeutics, David Witter, VP, Preclinical Research, Cullinan Oncology, Mehdi Rashighi, Founding Director, Connective Tissue Disease Clinic and Research Center, UMass Chan Medical School, Michelle Sidor, Director of Biology, DeepCure, George Poulogiannis, Team Leader, Signalling and Cancer Metabolism Group, Institute of Cancer Research, Gerhard Mueller, CSO, Anavo Therapeutics, Paul Barclay, VP, Global Program Head, LEO Pharma, Emmanuel Normant, VP, Preclinical Sciences, TG Therapeutics, Sandra Wiley, Senior Medical Scientist, MEI Pharma, Brian Hopkins, Director R and D, Biogen, Matthew Wongchenko, Principal Scientific Manager, Genentech